alexa Current status and future directions in induction chemotherapy for head and neck cancer.
Oncology

Oncology

Journal of Oncology Translational Research

Author(s): Argiris A

Abstract Share this page

Abstract As a component of multimodal therapy in locally advanced head and neck cancer, induction chemotherapy represents a strategy to reduce tumor burden and target distant metastases prior to definitive treatment. Although the addition of taxanes to the cisplatin and 5-fluorouracil induction regimen (TPF) has greatly benefitted outcomes in comparison with PF alone, recent phase III trials have not shown a survival advantage for TPF induction followed by chemoradiotherapy vs. chemoradiotherapy alone. While these trials may have been underpowered to demonstrate a survival benefit, additional phase III trials are ongoing, with highly anticipated results. "Next-generation" sequential regimens that include targeted agents such as cetuximab are emerging as an approach to increase activity while decreasing toxicity. In addition, patient selection based on individual disease characteristics may identify ideal candidates for induction therapy. These developments may result in personalized therapeutic regimens that improve clinical outcomes. Copyright © 2013 Elsevier Ireland Ltd. All rights reserved. This article was published in Crit Rev Oncol Hematol and referenced in Journal of Oncology Translational Research

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

  • Global Experts meeting on Oncology Case Reports
    Aug 29-31, 2017 London, UK
  • 25th World Congress on Cancer Science and Therapy
    October 18-20, 2017 Baltimore, Maryland, USA
  • 25th World Cancer Conference
    Oct 19-21, 2017 Rome, Italy
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords